Overview
NOCARH syndrome is characterized by neonatal-onset cytopenia, autoinflammation, rash, and hemophagocytic lymphohistiocytosis, driven by C-terminal variants in CDC42 leading to mitochondrial dysfunction and aberrant type I interferon signaling 1.Diagnosis
Identification of C-terminal CDC42 variants through genetic testing 1.
Clinical features include cytopenias, systemic inflammation, rash, and signs of hemophagocytic lymphohistiocytosis 1.
Elevated markers of inflammation and possibly hyperactivation of the pyrin inflammasome 1.Management
First-line treatments: Management often focuses on supportive care including transfusion support for cytopenias and anti-inflammatory therapies 1.
Adjunctive treatments: Inhibition of type I interferon signaling with ruxolitinib has shown efficacy in achieving remission in some cases 1.Special Populations
Pediatrics: NOCARH syndrome presents neonatally, emphasizing early diagnosis and intervention 1.
Comorbidities: Specific management strategies for comorbidities like severe infections requiring close monitoring and aggressive supportive care 1.Key Recommendations
Perform genetic testing to identify C-terminal CDC42 variants for definitive diagnosis (Evidence: Strong 1).
Consider ruxolitinib for patients with refractory autoinflammation, given its potential to inhibit type I interferon signaling and achieve remission (Evidence: Moderate 1).
Implement aggressive supportive care measures, including transfusion support and anti-inflammatory treatments, tailored to clinical presentation (Evidence: Expert opinion 1).References
1 Kapp FG, Kretschmer S, Beckmann CCA, Wäsch L, Molitor A, Carapito R et al.. C-terminal variants in CDC42 drive type I interferon-dependent autoinflammation in NOCARH syndrome reversible by ruxolitinib. Clinical immunology (Orlando, Fla.) 2023. link